CurrentMass General Brigham Health PlanPolicy N/A

Rituximab products prior authorization and coverage

Defines prior authorization, coverage criteria, dosing/authorization durations, and allowed indications (FDA-approved and off-label) for rituximab and biosimilars for Mass General Brigham Health Plan members across medical and pharmacy benefits.

Policy Summary

PayerMass General Brigham Health Plan

PolicyRituximab products prior authorization and coverage

Policy CodePolicy N/A

Change TypeMaterial updates to indication criteria and off-label use requirements

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and include clinical documentation of diagnosis and prior therapy trials per the indication-specific criteria.

SourceLink

POLICY UPDATE CHANGES

Mycophenolate was added to trials for polymyositis and dermatomyositis diagnoses.

Diagnosis criteria updated to include NHL subtypes directly in criteria rather than as a footnote.

Off-label indications were added and several off-label criteria (e.g., GVHD trials, ITP splenectomy requirement) were updated.

manyindications listed

variesinitial approval duration

up to 12 monthsreauthorization

multipleproducts included

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Authorization Rules

Coverage criteria by indication

Covered when ALL of the following are met for the specific indication (criteria vary by disease):

General authorization for members new to plan: Member new to plan currently receiving rituximab may be authorized if documentation of current treatment is provided (samples or manufacturer's patient assistance program supplies are excluded).

Non-Hodgkin's Lymphoma (NHL) indications: Diagnosis of CD20-positive B-cell NHL with ONE of: relapsed/refractory low-grade or follicular NHL using rituximab as a single agent; previously untreated follicular CD20-positive B-cell NHL treated with rituximab in combination with first-line chemotherapy; follicular CD20-positive B-cell NHL in complete or partial response to rituximab plus chemotherapy as single‑agent maintenance; previously untreated diffuse large B‑cell CD20‑positive NHL treated with rituximab plus CHOP or other anthracycline‑based regimens; non‑progressing low‑grade CD20‑positive B‑cell NHL treated with rituximab as a single agent after first‑line CVP chemotherapy.

Appropriate dosing required.

Rheumatoid arthritis (RA): Diagnosis of RA AND inadequate response, adverse reaction to, or contraindication to specified TNF inhibitors/biologics AND ONE of: requested agent will be used in combination with methotrexate OR contraindication/adverse reaction to methotrexate. Appropriate dosing required.

Granulomatosis with Polyangiitis (GPA) / Microscopic Polyangiitis (MPA): For induction: diagnosis of GPA or MPA AND inadequate response, adverse reaction, or contraindication to cyclophosphamide AND requested agent will be used in combination with a glucocorticoid within 30 days (unless contraindicated). Maintenance criteria and appropriate dosing apply.

Pemphigus vulgaris (PV): Diagnosis of PV AND requested agent will be used in combination with systemic corticosteroids OR documentation of inadequate response, adverse reaction to, or contraindication to systemic corticosteroids. Appropriate dosing required.

Pediatric mature B‑cell NHL and mature B‑cell acute leukemia (B‑AL): Previously untreated, advanced‑stage, CD20‑positive DLBCL or specified subtypes (Burkitt, Burkitt‑like) AND age criteria per policy AND appropriate dosing.

Chronic lymphocytic leukemia (CLL): Diagnosis of CLL with appropriate dosing per rituximab product requested.

Rituxan Hycela-specific: Diagnosis of DLBCL or follicular lymphoma with documentation of appropriate dosing. For non‑FDA‑approved B‑cell lymphomas, substitution of Rituxan Hycela allowed only if member received the first full IV dose of Rituxan.

Off‑label indications: Requests for listed off‑label uses (examples include autoimmune encephalitis, autoimmune epilepsy, GVHD, ITP, NMOSD maintenance, TTP, SLE, MS, IgG‑related disease, minimal change disease, polymyositis/dermatomyositis, myasthenia gravis, pemphigus foliaceus, and others) require documentation of appropriate diagnosis and prior conventional therapy trials as specified for each condition (inadequate response, adverse reaction, or contraindication to the listed agents).

Initial off‑label approval: 3 months; recertification: 12 months.

Continuation and duration

Continuation and duration rules:

Continuation of therapy: Resubmission by the prescriber will be accepted as evidence of a positive clinical response and may be used to continue authorization.

Initial and reauthorization durations: Initial approvals: RA — 2 weeks of therapy with a 4‑month duration; NHL/CLL and pediatric mature B‑cell NHL/B‑AL — 6 months; PV — 2 weeks of therapy with a 6‑month duration; induction therapy — 2 or 4 weeks of therapy (depending on dosing) with a 4‑month duration; GPA/MPA maintenance described per dosing. Reauthorizations: RA — 6 weeks of therapy with a 12‑month duration; NHL/CLL and pediatric — 12 months; PV — 2 weeks of therapy with a 12‑month duration; maintenance for GPA/MPA per policy (1 week of therapy with 4‑ or 6‑month duration depending on dosing).

For purposes of prior authorization for members who are new to the plan, rituximab obtained as samples or through a manufacturer's patient assistance program (PAP) is excluded and will not be considered documentation of current treatment. Authorization for new-to-plan members may be granted when the member is documented as currently receiving rituximab, but that documentation must reflect commercially supplied or otherwise verifiable therapy—not samples or PAP supplies. Providers should supply treatment records showing administration of the covered product (dose and route) when seeking continuity authorization for a transferring member.

This policy does not list additional standalone scenarios labeled as “not medically necessary.” Requests that do not meet the specified indication-specific criteria or lack required supporting documentation (for example, absence of the diagnosis, required prior therapy trials, or dosing information) may be denied. Providers should follow the indication-specific criteria and include the requested documentation to avoid denial.

Document-level Coding

Document-level codingmixed

N/A	No specific CPT/HCPCS/ICD codes listed in document

Prior Authorization and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for listed rituximab products across medical and pharmacy benefits. Requests must include clinical documentation supporting the diagnosis and prior therapy trials. Prior authorization may be granted for members new to the plan who are currently receiving treatment with rituximab, excluding when the product was obtained as samples or via manufacturer's patient assistance programs (PAP).

Applies to: Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima
Contact: Medical/Specialty Medications — Phone: 877-519-1908; Fax: 855-540-3693
Pharmacy Non-Specialty — Phone: 800-711-4555; Fax: 844-403-1029

Step Therapy

Step Therapy / Prior Trials Required

Many autoimmune and off-label indications require documentation of inadequate response, adverse reaction, or contraindication to specified prior therapies (step therapy). Examples include but are not limited to: rheumatoid arthritis (trial/failure or contraindication to multiple TNF inhibitors and other biologics; methotrexate combination unless contraindicated), autoimmune encephalitis and autoimmune epilepsy (failure or contraindication to IV glucocorticoids, IVIG, and plasma exchange), lupus nephritis (failure or contraindication to cyclophosphamide and mycophenolate), and other conditions listed under off-label uses.

Background and Context

Rituximab is a monoclonal antibody directed against CD20 on the surface of B-lymphocytes. By binding CD20, rituximab mediates B-cell depletion through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, reducing the number of circulating B cells. Clinically, this mechanism underpins rituximab’s use in B-cell malignancies (for example, non-Hodgkin’s lymphomas and chronic lymphocytic leukemia) and in a variety of autoimmune diseases where pathogenic B cells contribute to disease activity.

Key Definitions

Rituximab: mechanism of action

DefinitionMonoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes.

Primary mechanismBinds CD20 on B cells and activates complement-dependent cytotoxicity (CDC).

Additional cytotoxic mechanismEngages human Fc receptors to mediate antibody-dependent cellular cytotoxicity (ADCC).

Physiologic effectLeads to B‑cell depletion which can reduce signs and symptoms and slow structural progression in conditions such as rheumatoid arthritis and certain B‑cell lymphomas.

Target roleCD20 is involved in B‑cell cycle initiation and may function as a calcium channel; targeting CD20 disrupts B‑lymphocyte activity.